The METSCAN™ platform has helped identify key steps with maximum weightages, that are responsible for metastasis success. Currently, we are focused on building high throughput and high content screening platforms around the specific targets that are involved in such rate-limiting steps. This will empower us to build a pipeline for drug discovery, consisting of both biochemical and cell-based assays.